RayKnowChina Research Map
Shortlist

Nanchang University

南昌大学

NanchangUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.0%Leads about 1 in 99 of China's research papers on NPC

Led 24 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
24
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025
ThemesRadiotherapy techniqueSide effects & quality of lifeInduction / concurrent chemotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University14
  2. First Affiliated Hospital of Nanchang University6
  3. Affiliated Ganzhou Hospital of Nanchang University Counted in the group total1
  4. Affiliated Cancer Hospital of Nanchang University1
  5. Third Affiliated Hospital of Nanchang University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.2025European journal of medical researchFree full text
  2. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.2024Oral oncology
  3. Serum inflammatory markers as prognostic marker for nasopharyngeal carcinoma with liver metastasis: a multi-center retrospective study.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  4. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective2022BMJ openFree full text
Trials on ClinicalTrials.gov6
  1. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  2. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  3. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  4. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRTNot yet recruitingNCT04215510Study sitePhase 3Start 2021-03
  5. Clarify of Predictive Risk Factors of Chemotherapy-induced Liver InjuryStatus unknownNCT03069820Lead sponsorPhase 4Start 2017-02
  6. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Study sitePhase 2Start 2022-05

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.4%Leads under 1 in 100 of China's research papers on ESCC

Led 12 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesMolecular markers & genomicsImaging & AIEarly detection & endoscopy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University8
  2. Second Affiliated Hospital of Nanchang University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Entirely Intramural Growth Pattern: A Rare Presentation of Esophageal Squamous Cell Carcinoma and Review of the Literature.2025Zeitschrift fur Gastroenterologie
  2. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer.2026Cell reports. MedicineFree full text
  4. AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.2025Molecular genetics and genomics : MGG
  5. TRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12.2025Biochemistry and cell biology = Biochimie et biologie cellulaire
Trials on ClinicalTrials.gov6
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  2. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  3. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  4. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  5. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  6. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.2%Leads about 1 in 81 of China's research papers on HCC

Led 181 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
181
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University96
  2. First Affiliated Hospital of Nanchang University63
  3. Affiliated Ganzhou Hospital of Nanchang University Counted in the group total2
  4. Affiliated Cancer Hospital of Nanchang University1
  5. Fourth Affiliated Hospital of Nanchang University Counted in the group total1
  6. Third Affiliated Hospital of Nanchang University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE.2024La Radiologia medicaRCT
  2. Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma.2023Journal of the National Comprehensive Cancer Network : JNCCNRCT
  3. Biejia-Ruangan compound and incidence of hepatocellular carcinoma.2023Journal of hepatology
  4. Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter re2025World journal of surgical oncologyFree full text
  5. Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Study siteN/AStart 2026-10
  2. A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruitingNCT07156617Study siteStart 2025-10
  3. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  4. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  5. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  6. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.8%Leads about 1 in 56 of China's research papers on Stomach cancer ▲ from 1.3%

Led 173 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
173
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.8%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University98
  2. Second Affiliated Hospital of Nanchang University57
  3. Third Affiliated Hospital of Nanchang University Counted in the group total5
  4. Affiliated Tumor Hospital of Nanchang University1
  5. Affiliated Hospital, Nanchang University1
  6. Affiliated Jiujiang Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Adjuvant treatment and molecular mechanism of probiotic compounds in patients with gastric cancer after gastrectomy.2021Food & functionRCT
  2. A Network Information-Based Behavior Change Wheel for Populations at High Risk of Developing Gastric Cancer.2026Journal of cancer education : the official journal of the American Association for Cancer Education
  3. Clinical significance of the S204 phosphorylation of the Smad3 protein in combination with Ki67 for the metastasis and prognosis of gastric cancer.2025BMC gastroenterologyFree full text
  4. Short- and long-term outcomes of totally robotic versus robotic-assisted total gastrectomy for advanced gastric cancer: a single-center retrospective study.2025World journal of surgical oncologyFree full text
  5. Stratified and propensity score matching analysis of the effectiveness of fibrin glue in preventing postoperative bleeding after endoscopic submucosal dissection.2025Annals of medicineFree full text
Trials on ClinicalTrials.gov6
  1. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  4. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  6. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
3.0%Leads about 1 in 33 of China's research papers on Retinoblastoma ▲ from 1.8%

Led 9 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
0.9%Leads under 1 in 100 of China's research papers on Chordoma ▼ from 2.3%

Led 1 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.7%Leads about 1 in 38 of China's research papers on Osteosarcoma ▲ from 1.2%

Led 60 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
60
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.5%Leads about 1 in 65 of China's research papers on Gastrointestinal stromal tumour

Led 8 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University6
  2. Digestive Disease Hospital1
  3. Second Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.5%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 6 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University3
  2. Second Affiliated Hospital of Nanchang University1
  3. Ganzhou People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma ▼ from 3.6%

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.9%Leads under 1 in 100 of China's research papers on Myeloma ▲ from 0.4%

Led 16 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
16
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 002025
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University10
  2. First Affiliated Hospital of Nanchang University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCTFree full text
  2. The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.2024Scientific reportsFree full text
  3. A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.2024Technology in cancer research & treatmentFree full text
  4. Obstructive jaundice caused by pancreatic plasmacytoma secondary to multiple myeloma: A case report and literature review.2021Journal of digestive diseases
  5. Multiple myeloma with CD138 changed from positive to negative: A case report.2021Cytometry. Part B, Clinical cytometry
Trials on ClinicalTrials.gov6
  1. A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06999031Lead sponsorEarly phase 1Start 2024-09
  2. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  3. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  4. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)Not yet recruitingNCT07399444Study siteEarly phase 1Start 2026-01
  5. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  6. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesChildrenAntibody & targeted drugsMRD & relapse

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University1
  2. Affiliated Ganzhou Hospital of Nanchang University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.2%Leads about 1 in 80 of China's research papers on HLH

Led 5 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025
ThemesTreatment regimensDiagnosis & prognosisLymphoma & cancer-related HLH

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征
7.4%Leads about 1 in 13 of China's research papers on Atypical haemolytic uraemic syndrome New since 2021

Led 2 of 27 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (11.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University1
  2. First Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
3.1%Leads about 1 in 32 of China's research papers on Thrombotic thrombocytopenic purpura New since 2021

Led 2 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University1
  2. First Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.0%Leads about 1 in 97 of China's research papers on NMOSD New since 2021

Led 5 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025
ThemesImagingBiologic drugsAntibodies & diagnosis

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University4
  2. Ganzhou People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.8%Leads under 1 in 100 of China's research papers on Myasthenia gravis ▼ from 1.7%

Led 4 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025
ThemesEye-only (ocular) myasthenia

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.5%Leads about 1 in 40 of China's research papers on Moyamoya ▲ from 1.8%

Led 9 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University5
  2. Second Affiliated Hospital of Nanchang University3
  3. Changcheng Hospital, Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.6%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 6 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University4
  2. Second Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.0%Leads about 1 in 97 of China's research papers on Amyotrophic lateral sclerosis ▼ from 2.6%

Led 8 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University4
  2. Second Affiliated Hospital of Nanchang University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
2.4%Leads about 1 in 43 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 5 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.8%Leads about 1 in 56 of China's research papers on IgA nephropathy ▲ from 0.8%

Led 13 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Second Affiliated Hospital of Nanchang University10
  2. First Affiliated Hospital of Nanchang University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.2025BMC nephrology
  2. IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristics.2025Clinical and experimental rheumatology
  3. The efficacy of rituximab in the treatment of IgA vasculitis nephritis.2024Clinical and experimental medicine
  4. Changes in the spectrum of kidney diseases: a survey of 2803 patients from 2010 to 2018 at a single center in southeastern China.2022Renal failure
  5. IgA nephropathy associated with anti-PLA2R antibody positive: a case report.2022International urology and nephrology
Trials on ClinicalTrials.gov6
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  3. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  5. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  6. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis New since 2021

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University1
  2. Second Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Nanchang University1
  2. Second Affiliated Hospital of Nanchang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov